Incyte Genomics, Inc. (INCY) Reports Q4 EPS Loss of $0.44, Sales Top Expectations
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $126.75 -0.98%
Revenue Growth %: +7.3%
Financial Fact:
Income (loss) from operations: 22.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.3%
Financial Fact:
Income (loss) from operations: 22.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q4 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $25.65 million.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
- Morgan Stanley Downgrades Peloton Interactive (PTON) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
